#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
CHICAGO — Touted as one of Novartis’ blockbusters-to-be in 2020, the Incyte-discovered MET inhibitor capmatinib is being primed for a marketing application after final data from a mid-stage study suggested the drug has the ability to improve outcomes in patients with non small cell lung cancer (NSCLC) harboring a MET exon-14 skipping mutation — a subset that has no approved targeted therapy.
According to the NIH, MET exon 14 skipping occurs in roughly 5% of patients with NSCLC, which represents the most common form of lung cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.